Inhibikase and Fennec Pharmaceuticals release quarterly results for September

what happened

Earnings Summary, citing LSEG figures, says Inhibikase Therapeutics lost 10 cents a share on an adjusted basis in the three months to September 30, a smaller deficit than the 13-cent loss a year earlier. Nine analysts had forecast an 11-cent loss. Revenue was zero, in line with forecasts, and the net loss reached $20.5 million. Over the quarter the shares dropped 20.7% and are down 20.5% year to date.

Fennec Pharmaceuticals also beat expectations. Its adjusted earnings came in at 12 cents a share, against a six-analyst average of 9 cents. Revenue climbed 57.3% to $19.61 million, above the $18.81 million consensus, and net income was $4.64 million. The stock slipped 0.1% in the quarter but is up 38.2% this year.

Analysts rate both companies a consensus 'buy'.

why it matters

These are routine results from biotech and pharma names, so the broader market impact is limited. For investors in this group, the key points are Fennec's revenue beat and Inhibikase's narrower loss, set against a quarterly share price decline for Inhibikase.

tags

instruments